epoetin alfa, Epogen, Procrit
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: epoetin alfa
BRAND NAME: Epogen, Procrit
DRUG CLASS AND MECHANISM: Epoetin alfa is a man-made, injectable drug for treating anemia. Erythropoietin is a protein that normally is made in the body by the kidney. It causes the bone marrow to produce oxygen-carrying red blood cells. Under normal conditions, when the body senses a decrease in red blood cells or a deficiency in the supply of oxygen, more erythropoietin is produced, and this increases the number of red blood cells. When this natural mechanism is not working, it may become necessary to stimulate the bone marrow to produce red blood cells. The erythropoietin that is used for therapy, called epoetin alfa, is man-made. It is a product of the genetic engineering of ovarian cells of the Chinese hamster and is produced through recombinant DNA technology in bacteria. It does not cure the underlying cause of the anemia, and unless the underlying cause can be reversed, treatment with epoetin alfa must be continued indefinitely.
Epoetin alfa belongs to a class of drugs called colony-stimulating factors because of their ability to stimulate cells in the bone marrow to multiply and form colonies of identical cells. Other colony-stimulating factors include filigrastim (Neupogen) and sargramostim (Leukine). Epogen and Procrit are both epoetin alfa, but they are marketed by two different pharmaceutical companies. The FDA approved epoetin alfa in June 1989.
GENERIC AVAILABLE: No
PREPARATIONS: Vials containing liquid for injection: 2000, 3000, 4000, 10000, 20000 and 40000 U/ml as well as 20000 U/2ml
STORAGE: Epoetin alfa should be stored at 2-8 C (36-46 F). It should not be frozen. Multiple-use vials should be used within 21 days of the first use.
PRESCRIBED FOR: Epoetin alfa is used to treat anemia that is associated with chronic kidney failure in patients who are or will be receiving renal dialysis. It also is used to treat anemia in patients with HIV infection who are receiving zidovudine (Retrovir) and in patients with cancer who are receiving chemotherapy and develop anemia. Epoetin alfa may be used to replace transfusions of red blood cells in patients who are anemic and undergoing surgery. Epoetin alfa has not been shown to improve fatigue or quality of life in patients with cancer.
DOSING: Epoetin alfa is administered intravenously or subcutaneously (under the skin) at 50-100 units/kg of body weight, three times weekly. The dose is tailored to each patient based on targeted hemoglobin levels. Adult patients with cancer receiving chemotherapy may be treated with 40,000 units weekly or 150 units/kg 3 times weekly.
Zidovudine treated patients should receive 100 units/kg 3 times weekly.
Surgery patients should receive 300 units/kg per day daily for 14 days or 600 units/kg weekly. The smallest effective dose should be used.
In clinical trials, the risk of death or serious heart problems, and stroke occurred more often when epoetin alpha was administered to target a hemoglobin level greater than 11 g/dL. Epoetin alfa vials should not be shaken since the drug may be damaged, and bubbles may form that prevent some of the drug from being drawn up into the syringe during injection. Iron stores should be evaluated before therapy and supplemental iron should be administered if needed.
DRUG INTERACTIONS: No clinical studies have been done to demonstrate epoetin alfa drug interactions.
PREGNANCY: There are no studies of epoetin alfa use in pregnant women. Polyhydramnios and intrauterine growth restriction was reported in a small number of pregnant women who received epoetin alpha. Multiple dose vials contain benzyl alcohol and should not be administered to pregnant women.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index